vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and TAKEDA PHARMACEUTICAL CO LTD (TAK), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $4.3M, roughly 3390.7× TAKEDA PHARMACEUTICAL CO LTD). ASTRAZENECA PLC runs the higher net margin — 16.9% vs 3.4%, a 13.6% gap on every dollar of revenue.
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
AZN vs TAK — Head-to-Head
Income Statement — Q2 2025 vs Q1 2025
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $4.3M |
| Net Profit | $2.4B | $144.2K |
| Gross Margin | 82.9% | 66.5% |
| Operating Margin | 24.3% | 5.0% |
| Net Margin | 16.9% | 3.4% |
| Revenue YoY | 11.7% | — |
| Net Profit YoY | 27.0% | — |
| EPS (diluted) | $1.57 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q2 25 | $14.5B | $4.3M | ||
| Q2 24 | $12.9B | — | ||
| Q1 24 | — | $4.0M | ||
| Q2 23 | $11.4B | — | ||
| Q2 22 | $10.8B | — |
| Q2 25 | $2.4B | $144.2K | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | — | $317.0K | ||
| Q2 23 | $1.8B | — | ||
| Q2 22 | $360.0M | — |
| Q2 25 | 82.9% | 66.5% | ||
| Q2 24 | 83.1% | — | ||
| Q1 24 | — | 69.1% | ||
| Q2 23 | 82.8% | — | ||
| Q2 22 | 72.2% | — |
| Q2 25 | 24.3% | 5.0% | ||
| Q2 24 | 21.2% | — | ||
| Q1 24 | — | 12.2% | ||
| Q2 23 | 21.5% | — | ||
| Q2 22 | 5.0% | — |
| Q2 25 | 16.9% | 3.4% | ||
| Q2 24 | 14.9% | — | ||
| Q1 24 | — | 7.9% | ||
| Q2 23 | 15.9% | — | ||
| Q2 22 | 3.3% | — |
| Q2 25 | $1.57 | — | ||
| Q2 24 | $1.24 | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $1.17 | — | ||
| Q2 22 | $0.23 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | $2.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | $45.1B |
| Total Assets | $112.4B | $92.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q2 25 | $7.1B | $2.5B | ||
| Q2 24 | $6.9B | — | ||
| Q1 24 | — | $3.0B | ||
| Q2 23 | $5.7B | — | ||
| Q2 22 | $4.8B | — |
| Q2 25 | $44.8B | $45.1B | ||
| Q2 24 | $39.6B | — | ||
| Q1 24 | — | $47.3B | ||
| Q2 23 | $37.4B | — | ||
| Q2 22 | $36.0B | — |
| Q2 25 | $112.4B | $92.6B | ||
| Q2 24 | $104.3B | — | ||
| Q1 24 | — | $98.2B | ||
| Q2 23 | $96.5B | — | ||
| Q2 22 | $96.6B | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
